TABLE 5.
Univariate and multivariable analysis of PFS in the total patient population treated with bendamustine and rituximab (BR) and ibrutinib
| Variable | univariate | P | Multivariate | P |
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age (as continuous variable) | 1.05 (1.02‐1.09) | <0.01 | 1.06 (1.02‐1.10) | <0.01 |
| RAI 3‐4 vs 0‐2 | 1.09 (0.66‐1.79) | 0.73 | — | — |
| 11q‐ yes vs no | 2.13 (1.04‐4.37) | 0.04 | — | — |
| Time dx‐trx a (continuous variable) | 1.00 (0.99‐1.00) | 0.62 | — | — |
| interval dx‐trx a ≥ 36 vs < 36 months | 0.89 (0.57‐1.38) | 0.61 | — | — |
| Ibr vs. BR | 0.60 (0.36‐1.01) | 0.05 | 0.55 (0.33‐0.93) | 0.03 |
a
Interval between diagnosis and treatment